Journal Information
Share
Share
Download PDF
More article options
Visits
...
Original article
DOI: 10.1016/j.htct.2021.01.005
Open Access
Available online 11 March 2021
Coping with COVID-19 pandemic in blood transfusion services in West Africa: the need to restrategize
Visits
...
Henshaw Uchechi Okoroiwua,
Corresponding author
okoroiwuhenshaw@gmail.com

Corresponding author at: Haematology Unit, Department of Medical Laboratory Science, University of Calabar, Nigeria.
, Ifeyinwa Maryann Okafora, Enosakhare Aiyudubie Asemotaa, Christopher Ogar Ogara, Ikenna Kingsley Uchendub
a University of Calabar, Calagar, Nigeria
b University of Nigeria, Enugu Campus, Nsukka, Enugu, Nigeria
Received 06 July 2020. Accepted 07 January 2021
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (4)
Table 1. Incidence of COVID-19 in countries in West Africa, as of June 17, 2020.9,19
Table 2. Blood donation rate and proportion of voluntary donations in countries in West Africa.8
Table 3. Proportion of blood donations positive/reactive for transfusion-transmissible infections.8
Table 4. Proportion of donated blood units processed into components and also screened for TTIs.8
Show moreShow less
Abstract
Introduction

The West African region has been lagging in terms of the availability of, and accessibility to, safe blood. According to the 2016 World Health Organization (WHO) Global Status Report on Blood Safety and Availability, none of the West African countries met the WHO benchmark of 10 blood units per 1000 inhabitants. This study is aimed at discussing the blood transfusion status of West African countries in the pre-COVID-19 period and analyze the capacity to respond to the COVID-19 blood crisis, as well as to outline the panacea.

Methods

Secondary data were extracted from published reports, journal articles and web pages, reviewed and analyzed.

Result

All the West African countries have recorded confirmed COVID-19 cases and deaths. The confirmed cases have reached 55,697, with 1069 deaths and a fatality rate of 1.9%, as of June 17, 2020. The assessed countries lagged in most of the WHO benchmarks for effective blood transfusion services.

Conclusion

Blood transfusion services in the West African region lacked the basic benchmark practice and policy, are not coordinated and may find it hard to tackle the blood transfusion crisis created by the COVID-19 pandemic.

Keywords:
COVID-19
Coronavirus
SARS-CoV-2
Blood transfusion
West Africa
Full Text
Introduction

Blood transfusion is a lifesaving intervention that is included in the World Health Organization (WHO) list of essential medications.1–3 In Africa, and sub-Saharan Africa in particular, blood transfusion is critical in the management of varying pathologies, including malaria associated anemia, trauma, obstetric hemorrhage and neoplasms, among others.4–6 However, the availability of, and access to, safe blood has continued to be a challenge in Africa.7 The 2016 WHO report on blood safety and availability showed that the WHO African region contributed to only 5.6% of the 112.5 million blood donations globally. Moreover, it revealed that 67 countries (38 of which are in the WHO Africa region) reported collection of less than 10 whole blood donations per 1000 inhabitants per year in 2013 which is below the WHO benchmark. Only Mauritius and South Africa beat the par, with 39.7% and 18.0% donations per 1000 inhabitants, respectively.8

The west African sub-region is made up of 16 countries, with an estimated population of 401,359,000, accounting for approximately 5.16% of the global population (United Nations estimate).9 The proportion of the population donating blood ranged from 0.24% to 0.72%.7 An efficient, well established and functional national blood transfusion system is scantly available in the region, irrespective of the development of national blood transfusion policies by most of the countries.8

An outbreak of pneumonia was reported on December 31, 2019 in the city of Wuhan, Hubei Province, China, which was identified and subsequently named severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), belonging to the Beta coronavirus genus of the coronaviridae family on January 7, 2020.10–12 As of March 11, 2020, the World Health Organization declared the disease pandemic and named it COVID-19.13 It is a highly contagious respiratory disease. The principal symptoms of the disease include fever (98.6%), fatigue (69.6%), dry cough (59.4%) and dyspnea (43.0%).11,14 The incubation period of the virus varies from 1 to 14 days, with a mean value of 5 days.15 It is a respiratory tract infection primarily transmitted via respiratory droplets and contact. The maximum load of virus is present in the bronchoalveolar lavage fluid (93%).16 However, parenteral transmission has not been established, as only a few studies, such as one in Wuhan, China, which reported 6 out of 41 (14.6%) of the COVID-19 patient blood samples testing positive for COVID-19.17 Another study in China among blood donors has identified SARS-CoV-2 RNA in routine blood donations. In the study, 2430 blood donations (1656 platelet and 774 whole blood) collected between January 25, 2020 and March 4, 2020 were screened by real-time reverse transcription polymerase chain reaction (PCR) for SARS-CoV-2; in addition, almost 5000 samples collected between December 21, 2019 and January 22, 2020 were retrospectively tested. Four samples were positive for SARS-CoV-2. All four blood donors were asymptomatic at the time of collection, but two developed fever the day after donation.18 Similarly, there have been reports of the detection of SARS-CoV-2 in semen,19 the gastrointestinal tract, saliva and urine.20

As of June 17, 2020, there have been 8,043,487 confirmed cases and 439,487 deaths globally in 213 countries and territories and 2 conveyances.21 The COVID-19 pandemic started in western Africa in February 2020 in Nigeria,10 with Nigeria and Ghana being the most affected countries.

This study is aimed at discussing the blood transfusion status in the West African region in the pre-COVID-19 period and analyzing the capacity to respond to the blood demand during the pandemic of COVID-19, as well as discussing a possible panacea to improve services.

Methods

Research articles, case reports, report updates and other web pages were reviewed for blood transfusion services and practices. The WHO database was searched for the blood transfusion practice in the West African region and COVID-19 updates, while the Worldometere database was searched for country populations. The Pubmed database and Google advanced search were used to search for COVID-19/SARS-CoV-2/nCOV-related articles. The data extracted were presented as frequencies and proportions (%) to weigh the capacity to respond to the blood demands in the pre- and intra-COVID-19 periods.

ResultsCOVID-19 pandemic in West Africa

West Africa is composed of 16 countries: Benin, Burkina Faso, Cape Verde (Cabo Verde), Cote d’Ivoire, Gambia, Ghana, Guinea Conakry, Guinea Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone and Togo (Figure 1). The region boasts 30% and 28% of Africa’s population and gross domestic product (GDP), respectively.22 All of these countries belong to the Economic Community of West Africa (ECOWAS), except Mauritania. The ECOWAS has a GDP of US$ 716.7 billion.23

Figure 1.

Map of West Africa showing the studied countries and the location in Africa (Map is original from the authors).

(0.24MB).

The first case of COVID-19 in West Africa was reported in Nigeria on February 27, 2020. Subsequently, the pandemic has escalated to other West African countries. As of the month of March 2020, Nigeria, Cote d’Ivoire and Senegal had the highest number of confirmed COVID-19 cases. On the other hand, Nigeria, Mauritania and Senegal recorded the highest number of confirmed COVID-19 deaths. Niger, Liberia and Burkina Faso had the highest fatality rates. The highest numbers of new cases were recorded in Cote d’Ivorie, Nigeria and Ghana (Table 1).

Table 1.

Incidence of COVID-19 in countries in West Africa, as of June 17, 2020.9,19

Country  Population  Date of index case (2020)  Confirmed cases  Confirmed deaths  New cases  Fatality (%) 
Benin  12,123,200  March 16  532  49  1.7 
Burkina Faso  20,903,273  March 9  895  53  5.9 
Cape Verde  555,987  March 20  781  21  0.9 
Cote d’Ivoire  26,378,274  March 11  5679  46  595  0.8 
Gambia  2,416,668  March 17  34  0.2.9 
Ghana  31,072,940  March 12  12,193  58  229  0.5 
Guinea Conakry  13,132,795  March 13  4639  26  67  0.6 
Guinea Bissau  1,968,001  March 25  1492  15  32  1.0 
Liberia  5,057,681  March 16  509  33  11  6.5 
Mali  20,250,833  March 25  1885  106  25  5.6 
Mauritania  4,649,658  March 13  1887  91  104  4.8 
Niger  24,206,644  March 19  1016  66  36  6.5 
Nigeria  206,139,589  February 27  17,146  424  490  2.5 
Senegal  16,743,927  March 2  5247  70  157  1.3 
Sierra Leone  7,976,983  March 31  1225  51  49  4.2 
Togo  8,278,724  March 6  537  13  2.4 
Blood transfusion practice in West Africa

None among the 16 West African countries reached the WHO benchmark of 10 whole blood collections per 1000 inhabitants. The highest values, namely 7.2, 6.6 and 5.9, were reported in Gambia, Benin and Togo, respectively. Thirteen (13) out of the 16 countries in West Africa have developed national blood policies. However, the implementation of these policies has been strongly restrained, partly due to the lack of funding, political will and open-mindedness to innovative ideas on safe donor recruitments.24–26 Only Benin, Togo, Senegal and Cape Verde had high proportions of voluntary non-remunerated donation. The value for Nigeria was only reported by the National Blood Transfusion Service Center in Abuja. The remaining sources of blood were via family replacement and commercially remunerated donors (Table 2).

Table 2.

Blood donation rate and proportion of voluntary donations in countries in West Africa.8

Country  Donation per 1000 inhabitants  Proportion of voluntary donations (%)  No. of hospitals performing blood transfusion  No. of hospitals performing component preparation  National blood policy 
Benin  6.7  92.1  50  Absent 
Burkina Faso  3.7  100  93  Absent 
Cape Verde  5.6  77.3  Present 
Cote d’Ivoire  4.4  100  200  Present 
Gambia  7.2  24.1  11  Present 
Ghana  5.4  27.1  257  Present 
Guinea Conakry  2.4  14.7  42  Present 
Guinea Bissau  2.7  19.9  Present 
Liberia  No data  No data  38  Absent 
Mali  3.1  30.4  13  Present 
Mauritania  2.5  31.3  24b  Present 
Niger  3.5  36.3  47  Present 
Nigeria  No data  94.2a  22c  Present 
Senegal  4.5  79.4  141  Present 
Sierra Leone  5.2  9.7  30  Present 
Togo  5.9  98.3  No data  Present 
a

Data from only NBTS Abuja.

b

Data from 2012.

c

Data from 2011.

The proportion of transfusion-transmissible infections (TTIs) in donated blood units in the West African countries is high, ranging from 0.1 to 6.7 for HIV, 1.6 to 16.6 for HBV, 0 to 4.9 for HCV and 0.02 to 4.2 for syphilis (Table 3). A study in Nigeria2 in 2018 showed that 14.96% of donors were infected with at least one of the four major transfusion-transmissible infections. The TTI prevalences were 4.2%, 4.1%, 3.1% and 3.6% for HIV, HBV, HCV and syphilis, respectively. Another study in Burkina Faso27 in 2012 showed the TTI prevalences of 1.8%, 13.4%, 6.3% and 2.1% for HIV, HBV, HCV and syphilis, respectively. An additional study in Senegal28 reported the TTI prevalence of 3.5 per 100,000 donations for HIV, 102.45 per 100,000 donations for HBV and 138 per 100,000 donations for HCV.

Table 3.

Proportion of blood donations positive/reactive for transfusion-transmissible infections.8

Country  Transfusion-transmissible infection
  HIV (%)  HBV (%)  HCV (%)  Syphilis 
Benin  1.9  7.4  4.9  1.5 
Burkina Faso  2.2  9.7  4.8  1.7 
Cape Verde  0.1  1.6  0.1  0.6 
Cote d’Ivoire  0.4  5.6  1.7  0.6 
Gambia  No data  No data  No data  No data 
Ghana  2.4  6.9  2.2  4.2 
Guinea Conakry  2.7  7.7  1.0  1.1 
Guinea Bissau  6.7  11.5  0.7  0.1 
Liberia  No data  No data  No data  No data 
Mali  2.1  17.4  3.0  <0.1 
Mauritania  0.2  16.6  0.2 
Niger  2.3  8.5  1.5  1.0 
Nigeria  1.4  5.1  2.0  0.8 
Senegal  0.2  9.7  0.2  0.2 
Sierra Leone  4.6  9.5  1.2  1.6 
Togo  0.8  4.5  <0.1  0.2 

<0.1 = 0.02.

Most of the countries in West Africa do not effectively practice blood component preparation. Especially Liberia, Guinea Bissau, Guinea Conakry, Sierra Leone, Gambia, Niger and Ghana were found wanting in this. They possibly lack facilities for component preparation and hence, perform the transfusion of whole blood.7,24 Only Mauritania, Burkina Faso, Cape Verde, Cote d’ Ivoire, Togo and Senegal were found above par in terms of blood component preparation. Most of the countries screened all donated blood units for HIV, HBV, HCV and syphilis, except Gambia, Togo and Liberia, where HBV, HCV and syphilis screening were skipped at times (Table 4).

Table 4.

Proportion of donated blood units processed into components and also screened for TTIs.8

Country  Proportion of blood units processed into components (%)  Proportion of donated units screened for TTIs
    HIV (%)  HBV (%)  HCV (%)  Syphilis (%) 
Benin  No data  100  100  100  100 
Burkina Faso  91.4  100  100  100  100 
Cape Verde  98.9  100  100  100  100 
Cote d’Ivoire  94.5  100  100  100  100 
Gambia  100  25.9  17.5  No data 
Ghana  16.6  100  100  100  100 
Guinea Conakry  0.8  100  100  100  100 
Guinea Bissau  100  100  100  100 
Liberia  100  100  100  82.1 
Mali  32.1  100  100  100  100 
Mauritania  100  100  100  100  100 
Niger  1.6  100  100  100  100 
Nigeria  No data  100  100  100  100 
Senegal  51.8  100  100  100  100 
Sierra Leone  100  100  100  100 
Togo  66.4  100  100  100  66.4 
DiscussionBlood availability and safety during COVID-19 pandemic

The COVID-19 pandemic has had an enormous impact on almost all aspects of life, including the blood transfusion practice, number of blood donations, blood safety and movement of consumables used for blood transfusion screening. Based on data from a previous survey on the blood transfusion practice by the WHO and an early alert from the sub-Saharan region on the scarcity of blood with the onset of the pandemic,29,30 we discuss the preparedness and panacea to tackle the possible blood supply shortage.

Just as previous epidemics (SARS epidemic of 2003, influenza pandemic of 2009), the COVID-19 pandemic has been widely reported to lead to the decline in the number and availability of blood donors.11,31–34 This decline in blood donors partly stems from the fear in the healthy population that they might get infected while visiting a high-risk areas, such as hospitals and blood transfusion centers, and even in transit.11 Furthermore, the mass lockdown in many countries has also made it difficult for blood donors to move from place to place and blood transfusion centers to run donation drives and camps. The poor voluntary blood donation observed in most of the countries in West Africa makes it difficult to adapt to the pandemic crises, as voluntary blood donation would be best fitted to adapt in this period, considering that it is mostly driven by altruism.

Moreover, the government restrictions in most parts of the world in the attempt to curtail the COVID-19 pandemic also adversely affects the supply chain of consumables used in blood transfusion services. The ban on international flights and restrictions in interstate travels limits the conveyance and supply of blood transfusion consumables and, in some cases, adds extra cost. In addition, the decreased workload as a result of the pandemic and wastage of reagents meant for daily maintenance of automated equipment, as well as the unnecessary expiration of reagents due to a decreased workload add to the list.11 The possibility of maneuvering these challenges lies in effective, functional national blood transfusion service centers and effective blood transfusion policy.

The safety of the blood donor and the recipient is paramount in the blood transfusion practice. Hence, there is a need for the constant monitoring of donors and recipients in the event one develops an infection suggestive of a transfusion-transmissible infection. Although parenteral transmission of COVID-19 has not been established, there are theoretical reports of detection of the viral RNA in blood.16,35–38

In view of the blood transfusion status in the countries of West Africa listed above, it is empirically difficult for these countries to respond effectively to an emergency, given the scarcity of blood posed by the COVID-19 pandemic. The pillars of an effective and efficient blood transfusion service are anchored on voluntary non-remunerated donation, a well-established and well managed nationally coordinated blood transfusion service and a well developed and implemented national blood transfusion policy. As evident in the data above, most of the countries in West Africa rely on familial replacement and commercially remunerated blood donors. These classes of donors are not altruistic, but rather are driven by the remuneration impulse. Hence, the same are classified as a high-risk group. Remunerated blood donors have been documented to express higher seropositivity for transfusion-transmissible infections than voluntary donors.2,39–41 Furthermore, this pandemic period is quite a restricted one and donors who are not motivated to save lives might not be willing to submit themselves to the rigorous process of blood donation at this time. Moreover, the lack/poor practice of blood components separation in most of the countries is counterproductive in this pandemic period, in which the demand for blood is relatively low. The donation and transfusion of whole blood for most indications for blood transfusion is a common practice in most hospital-based blood transfusion services (which are the majority) in most sub-Saharan countries.5,42,43 Aside from the human resources and logistic aspects, there is the absence or non-implementation of blood policies in most of the countries in West Africa, as well as the absence of contingency plans for blood transfusion services in crises, such as the current COVID-19 pandemic period.7 Such neglect in a region primed with high infant and maternal mortality7 and infectious disease outbreaks, weighs in on the downside of the situation. Benin, Guinea Conakry, Nigeria, Liberia and Togo are still battling with the latent Lassa fever epidemic.

PanaceaInclusion of blood transfusion services in emergency response team

As part of the palliative measures to curtail the COVID-19 crises, the WHO has issued guidelines on maintaining a safe and adequate blood supply during the COVID-19 pandemic. It advised a national, rather than a sub-national or local approach. The need to include blood services in the national outbreak response through experts linked to the national emergency response team.44 This will go a long way to air the importance of blood transfusion in a time of crisis and promote the inclusion of same on priority list.

Establishment of blood management information system

A lesson learnt from China on blood management during the pandemic was the establishment of the blood management information system. The implementation of such an information system helps optimize the blood supply chain. This allows for the conveyance of blood or donors from a bountiful area to a place of need.31 Such an arrangement helps spread out and balance excesses and deficits in the blood supply across the various parts of the country.

Practice of social media medicine

The world has become a global village and social media has become an important media for conveying and receiving information. One of the lessons learnt from the Chinese medical team in blood management in the current pandemic was the use of social media to recruit blood donors. The Chinese Society of Blood Transfusion (CSBT), in lieu of blood drives, made a public appeal for blood donation via the We Chat (a social media), in which indicated donors were invited and appointments were made for donations, while observing social distancing.31 The same can be replicated in West Africa using the more popular social media in the region, such as Facebook, Twitter, Instagram and others.

Use of pharmacological agents

In pandemics, such as the current COVID-19, one of the best approaches to minimize the blood shortage is the use of pharmacological agents instead of transfusing blood. The use of desmopressin in the treatment of mild hemophilia, in lieu of blood transfusion, and the use of the vasoconstrictor agent aprotinin to reduce blood loss at the operative site have been recommended. Furthermore, fluid replacement volume expanders such as crystalloids or colloids are good alternatives to blood transfusion in this pandemic period. In addition, the use of hematinic is a good alternative for anemic patients.32

Issue of appointment letters and mobile blood drives

Some blood centers have devised an innovative method of recruiting donors via the issue of appointment letters to voluntary blood donors to get individual access to the blood centers during the lockdown.33 Another perspective to this is the mobile blood drive that entails meeting the voluntary blood donors at home. In the pandemic period, regular voluntary donors are preferable. First-time donors and those who have not donated blood in the last five years are high-risk donors in the period of pandemic.45

The use of “lowest hanging fruit” option

Some clinicians have suggested the application of the “lowest hanging fruit” option to balance the demand and supply of blood and blood products during the pandemic. A typical example is the single unit policy called “why give 2 when 1 will do?” for erythrocytes does more to reduce overall transfusion requirements than simply monitoring the hemoglobin trigger.46 Other ways to achieve this approach entail cell salvage during surgery, minimally invasive surgical procedures and more.46

Nevertheless, this study might be potentially prone to varying limitations. First, the study extracted data retrospectively and missing data were observed in some cases. Secondly, the theme of the study is anchored on the previous survey, an early alert on blood availability during the pandemic and the authors’ day-to-day perceptions to demonstrate the weakness of the region in the blood transfusion practice in view of tackling the COVID-19 challenge.

Conclusion

The analysis of the blood transfusion practice in the pre-COVID-19 period in the countries in West Africa shows the unpreparedness to arrest the wave of blood chain shortage that is arising across the globe, even in developed countries, owing to the COVID-19 pandemic. The loophole the pandemic has exposed in terms of the blood transfusion practice has been harnessed by developed countries and should serve as an opportunity to strengthen the blood transfusion practice in West Africa. There is the need to adopt innovative ideas, as well as to employ advocacy and novel campaigns.

Author contributions

HUO conceived the study, performed the literature search, analyzed the data, designed the map and prepared the initial manuscript draft; IMO performed the literature search and analyzed the data; EAA analyzed the data; COO analyzed the data, and; IKU analyzed the data. All authors read and approved the final manuscript.

Conflicts of interest

The authors declare no conflicts of interest.

References
[1]
A. Weimer, C.T. Tagny, J.B. Tapko, C. Gouws, A.A. Tobian, P.M. Ness, et al.
Blood transfusion in sub-saharan Africa: a literature review of changes and challenges in the 21st century.
Transfusion, 59 (2019), pp. 412-427
[2]
H.U. Okoroiwu, I.M. Okafor, E.A. Asemota, D.C. Okpokam.
Seroprevalence of transfusion transmissible infections (HBV, HCV, SYPHILIS AND HIV) among prospective blood donors in a tertiary health care facility in Calabar, Nigeria; an eleven years evaluation.
BMC Public Health, 18 (2018), pp. 645
[3]
H.U. Okoroiwu, E.A. Asemota.
Blood donors deferral prevalence and causes in a tertiary health care hospital, southern Nigeria.
BMC Health Serv Res, 19 (2019), pp. 510
[4]
R. Idro, J. Aloyo.
Manifestations, quality of emergency care and outcome of severe malaria in Mulago Hospital, Uganda.
Afr Health Sci, 4 (2004), pp. 50-57
[5]
H.U. Okoroiwu, I.M. Okafor.
Demographic characteristics of blood and blood components transfusion recipients and pattern of blood utilization in a tertiary health institution in southern Nigeria.
BMC Haematol, 18 (2018), pp. 16
[6]
A.T. Makuria, D. Gebremichael, H. Demoz, A. Hadush, Y. Abdella, Y. Berhane, et al.
Obstetric hemorrhage and safe blood for transfusion inEthiopia: the challenges of bridging the gap.
Transfusion, 57 (2017), pp. 1-6
[7]
J.B. Tapko, K.T. Kanno.
Coping with Ebola in transfusion services in West Africa.
ISBT Sci Ser, 11 (2016), pp. 285-291
[8]
World Health Organization 2016.
Global status report on blood safety and availability.
World Health Organization, (2017),
[9]
Worldometer. West Africa Population. Available at: https://www.worldometers.info/world-population/western-africa-population/.
[10]
H.U. Okoroiwu, I.K. Uchendu, C.O. Ogar, I.M. Okafor.
COVID-19 in Nigeria: situation update and combative measures taken by the government.
Germs, (2020), pp. 274-278
[11]
Y. Dhiman, G.K. Patidar, S. Arora.
Covid-19 pandemic — response to challengesby blood transfusion services in India: a review report.
ISBT Sci Ser, 0 (2020), pp. 1-9
[12]
C.O. Ogar, H.U. Okoroiwu, E.I. Obeagu, J.E. Etura, D.A. Abunimye.
Assessment of blood supply and usage pre- and during COVID-19 pandemic: a lesson from non-voluntary donation.
Transfus Clin Biol, 28 (2021), pp. 68-72
[13]
WHO director generals opening remarks at the media briefing on covid 19-11 March, (2020),
[14]
D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu, J. Zhang, et al.
clinical characteristics of 138 hospitalized patients with 2019 novel corona virus — infected pneumonia in Wuhan China.
JAMA, 323 (2020), pp. 1061-1069
[15]
Q. Li, X. Guan, P. Wu, X. Wang, L. Zhou, Y. Tong, et al.
Early transmission by dynamics in Wuhan China, of novel corona virus. Infected pneumonia.
Engl J Med, 382 (2020), pp. 1199-1207
[16]
W. Wang, Y. Xu, R. Gao, R. Lu, K. Han, G. Wu, et al.
Detection of SARS-COV-2 in different types of clinical specimens.
JAMA, 323 (2020), pp. 1843-1844
[17]
C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, et al.
clinical features of patients infected with 2019 novel corona virus in Wuhan China.
[18]
L. Chang, L. Zhao, H. Gong, L. Wang, L. Wang.
Severe acute respiratory syndrome coronavirus 2 RNA detected in blood donations.
Emerg Infect Dis, 26 (2020), pp. 1631-1633
[19]
D. Li, M. Jin, P. Bao, W. Zhao, S. Zhang.
Clinical characteristics and results of semen tests among men with corona virus disease 2019.
[20]
W. Guan, Z. Ni, Y. Hu, W. Liang, C. Ou, J. He, et al.
Clinical characteristics of corona virus disease 2019 in China.
N Engl J Med, 382 (2020), pp. 1708-1720
[21]
World Health Organization. WHO Corona virus disease (COVID-19) dash board. Available from: https://covid19.who.int.
[22]
ECOWAS. ECOWAS Common external tariff (CEF): achievements, challenges and prospectus. ECOWAS, 2016 Annual Report.
[23]
United Nations Conference on Trade and Development statistical database 2016. Available from: http://unctadstat.unctad.org/EN/Index.html. [Cited 18 June 2020].
[24]
J.B. Tapko, B. Touse, G. Sambo.
Status of blood safety in WHO African region: report of the 2010 survey.
World Health Organization: regional office of Africa. Brazaville: WHO/AFRO Library Cataloguing Publication, (2014),
[25]
J.B. Tapko, P. Mainuka, A.J. Diarra-Nana.
Status of blood safety in WHO African region: report of the 2006 survey.
World Health Organization: regional office of Africa. Brazzaville: WHO/AFRO Library Cataloguing Publication, (2009),
[26]
O. Erhabor, T.C. Adias, A.S. Mainasara.
Provisions of safe blood transfusion services in low income setting in West Africa, case study of Nigeria.
Adv Med Biol, 59 (2013), pp. 1-58
[27]
B.M. Nagalo, C. Bisseye, M. Sanou, K. Kienou, Y.K. Nebié, A. Kiba, et al.
Seroprevalence and incidence of transfusion transmissible infectious disease among blood donors from regional blood transfusion centres in Burkiba Faso, West Africa.
Trop Med Int Health, 17 (2012), pp. 247-253
[28]
A.O. Toure-Fall, T. Dieye, A. Sall, M. Diop, M. Seck, S. Diop, et al.
Residual risk of transmission of HIV and HCV, in Senegalese national blood bank from 2003 to 2005.
Transfus Clin Biol, 16 (2009), pp. 439-443
[29]
M. Kasanga, S. Mudenda, T. Gondwe, M. Chileshe, B. Solochi, J. Wu.
Impact of COVID-19 on blood donation and transfusion services at Lusaka provincial blood transfusion centre, Zambia.
Pan Afr Med J, 35 (2020), pp. 74
[30]
A.M.S. Sayedahmed, A.A. Ali, S.B. Ali, H.S. Ahmed, S.F. Shrif, N.A. Ali.
Coronavirus disease (COVID-19) and decrease in blood donation: a cross section study from Sudan.
ISBT Sci Ser, 0 (2020), pp. 1-5
[31]
X. Cai, M. Ren, F. Chen, L. Li, H. Lei, X. Wang.
Blood transfusion during the COVID-19 outbreak.
Blood Transfus, 18 (2020), pp. 79-82
[32]
M. Kasanga, S. Mudenda, T. Gondwe, M. Chileshe, B. Solochi, J. Wu.
Impact of COVID-19 on blood donation and transfusion services at Lusaka provincial blood transfusion center, Zambia.
[33]
M. Raturi, A. Kasum.
the blood supply management amid the COVID-19 outbreak.
Transfus Clin Biol, 27 (2020), pp. 147-151
[34]
A.I. Yahia.
Management of blood supply and demand during COVID-19 pandemic in King Abdullah Hospital, Bisha, Saudi Arabia.
Transfus Apher Sci, 59 (2020),
[35]
L.M. Katz.
Is SARS‐CoV‐2 transfusion transmitted?.
Transfusion, 60 (2020), pp. 1111-1114
[36]
C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, et al.
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
[37]
W. Wang, Y. Xu, R. Gao, R. Lu, K. Han, G. Wu, et al.
Detection of SARS‐CoV‐2 in different types of clinical specimens.
JAMA, 323 (2020), pp. 1843-1844
[38]
W. Zhang, R.‐H. Du, L. Bei, X.S. Zheng, X.L. Yang, B. Hu, et al.
Molecular and serological investigation of 2019‐nCoV infected patients: implication of multiple shedding routes.
Emerg Microbes Infect, 9 (2020), pp. 386-389
[39]
S.G. Ahmed, A.W. Hassan.
Viral infectivity markers in donor blood; a retrospective study of three donor categories.
Blood Transfus, 2 (2000), pp. 75-80
[40]
M. Birhaneselassie.
Prevalence of transfusion transmissible infections in donors in Ethiopia blood bank between 2009 and 2013 and donation factors that will improve the safety of the blood supply in underdeveloped countries.
Lab Med, 42 (2016), pp. 134-139
[41]
N. Siraj, O.O. Achila, J. Isaac, E. Menghisteab, M. Haileniariam, S. Hagos.
Seroprevalence of transfusion transmissible infections among blood donors at national blood transfusion service, Eritrea: a seven-year retrospective study.
BMC Infect Dis, 18 (2018), pp. 264
[42]
M. Tamene, A. Tsegaye, A. Birhanu, M. Birhaneselassie.
Assessment of transfusion utilization and patient outcomes at the largest referral and university in Addis Ababa, Ethiopia.
ISBT Sci Ser, 11 (2016), pp. 7-14
[43]
P.O. Ayuketah, C.T. Tagny, N.P. Koki.
Assessment of clinical blood transfusion practice in a pediatric tertiary hospital in Cameroon.
J Blood Disord Ther, 1 (2019), pp. 101
[44]
World Health Organization.
Maintaining a safe and adequate blood supply during the pandemic outbreak of corona virus disease (COVID-19).
WHO, (2020),
[45]
World Health Organization.
Blood donor selection: guidelines on assessing donor suitability for blood donation.
WHO, (2012),
[46]
E.A. Gehrie, S.M. Frank, S.M. Goobie.
Balancing supply and demand for blood during COVID-19 pandemic.
Anesthesiology, 133 (2020), pp. 16-18
Copyright © 2021. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular
Idiomas
Hematology, Transfusion and Cell Therapy

Subscribe to our newsletter

Article options
Tools